Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial.

BACKGROUND Human immunodeficiency virus (HIV)-infected patients have decreased immune response to vaccines. Few data are available about pandemic flu vaccination in this population. METHODS We conducted a multicenter, patient-blinded, randomized trial in a cohort of HIV-infected adults. Patients received 2 injections 21 days apart of a AS03(A)-adjuvanted H1N1v vaccine containing 3.75 μg hemagglutinin (HA) or a nonadjuvanted H1N1v vaccine containing 15 μg HA to assess hemagglutination inhibition (HI) response and safety. RESULTS A total of 309 patients were randomized, and 306 were vaccinated. After the first vaccine dose, HI titers ≥1:40 were observed in 93.4% of the patients in the adjuvanted group (A group) (n = 155) and in 75.5% in the nonadjuvanted group (B group) (n = 151) (P < .001); seroconversion rates were 88.8% and 71.2%, and factor increases in geometric mean titers (GMT) of 21.9 and 15.1, respectively. After 2 injections, 98.6% of patients of the A group and 92.1% of the B group demonstrated HI titers ≥1:40 (P = .018); seroconversion rates were 96.5% and 87.1%, respectively, and factor increases in GMT were 45.5 and 21.2, respectively. The majority of adverse events were mild to moderate in severity; no impact on CD4+ cell count or viral load has been detected. CONCLUSIONS In HIV-1-infected adults, the AS03(A)-adjuvanted H1N1v vaccine yielded a higher immune response than did the nonadjuvanted one, with no impact on HIV infection.

[1]  Anthony S. Fauci,et al.  Influenza vaccines for the future. , 2010, The New England journal of medicine.

[2]  I. Frank,et al.  Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals , 2010, AIDS.

[3]  M. Bickel,et al.  Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients , 2010, AIDS (London).

[4]  J. Devaster,et al.  Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. , 2010, Vaccine.

[5]  K. Hoschler,et al.  Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. , 2009, The New England journal of medicine.

[6]  X. Zhang,et al.  A novel influenza A (H1N1) vaccine in various age groups. , 2009, The New England journal of medicine.

[7]  C. Wichems,et al.  Response to a monovalent 2009 influenza A (H1N1) vaccine. , 2009, The New England journal of medicine.

[8]  Felipe García,et al.  Influence of a vaccination schedule on viral load rebound and immune responses in successfully treated HIV-infected patients. , 2009, AIDS research and human retroviruses.

[9]  E. Janoff,et al.  Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. , 2009, The Lancet. Infectious diseases.

[10]  H. Furrer,et al.  Randomized, double-blind comparative trial of subunit and virosomal influenza vaccines for immunocompromised patients. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  L. Sticchi,et al.  Safety and Immunogenicity of Two Influenza Virus Subunit Vaccines, with or without MF59 Adjuvant, Administered to Human Immunodeficiency Virus Type 1-Seropositive and -Seronegative Adults , 2007, Clinical and Vaccine Immunology.

[12]  R. G. Das,et al.  Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: an international collaborative study. , 2007, Vaccine.

[13]  S. Oka,et al.  Efficacy and Immunologic Responses to Influenza Vaccine in HIV-1-Infected Patients , 2005, Journal of acquired immune deficiency syndromes.

[14]  K. Neuzil,et al.  Cardiopulmonary Hospitalizations During Influenza Season in Adults and Adolescents With Advanced HIV Infection , 2003, Journal of acquired immune deficiency syndromes.

[15]  R. Bugarini,et al.  Antibody responses and HIV-1 viral load in HIV-1-seropositive subjects immunised with either the MF59-adjuvanted influenza vaccine or a conventional non-adjuvanted subunit vaccine during highly active antiretroviral therapy. , 2003, Vaccine.

[16]  D. Skiest,et al.  Comparison of the effects of acute influenza infection and Influenza vaccination on HIV viral load and CD4 cell counts. , 2003, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[17]  C. V. Hoecke,et al.  Ten Years of Experience with the Trivalent Split-Influenza Vaccine, Fluarix™ , 2002 .

[18]  K. Nichol,et al.  Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome. , 2001, Archives of internal medicine.

[19]  K. Neuzil,et al.  Influenza-associated morbidity and mortality in young and middle-aged women. , 1999, JAMA.

[20]  Programmierbarer Thermoblock,et al.  From industry , 1991 .